Skip to main content
. 2014 Sep 29;111(41):14900–14905. doi: 10.1073/pnas.1407808111

Fig. 5.

Fig. 5.

Antitumor activity and toxicity of HFn-Dox NPs. HT-29 tumor cells were implanted s.c. into mice on day 0. Mice were treated with HFn-Dox (20 mg/kg Dox equivalents; n = 6), Doxil (20 mg/kg Dox equivalents; n = 7), free Dox (5 mg/kg; n = 8), HFn nanocages (480 mg/kg; n = 8), or PBS (n = 6) at day 9. (A) Tumor growth curves for mouse groups are indicated. (B) Animal survival curves in different groups. Asterisks indicate P = 0.0004 and 0.0007 for HFn-Dox compared with free Dox and Doxil, respectively (Kaplan–Meier). (C) The effect of different treatments on mouse body weight (bars represent means ± SD, n = 4–8).